Company news
PharmaEssentia Corp. news in 2023
PharmaEssentia Corp.'s news releases, calls and decks from 2023, newest first.
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
November 2, 2023
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate
October 3, 2023
PharmaEssentia Included in FTSE Russell Indices
September 18, 2023
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
August 4, 2023
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera
June 30, 2023
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
June 2, 2023
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
May 23, 2023